中聯重科(01157.HK)調整股票期權行權價格
格隆匯 10 月 30日丨中聯重科(01157.HK)公告,中聯重科股份有限公司(以下簡稱“公司”)於2020年10月30日召開第六屆董事會2020年度第六次臨時會議審議通過了《關於調整股票期權行權價格的議案》。
根據上述董事會決議,由於公司於2020年10月27日實施了2020年半年度權益分派方案,公司董事會擬按照《中聯重科股份有限公司2017年股票期權及限制性股票激勵計劃(草案)》(以下簡稱“《激勵計劃(草案)》”)的規定,將2017年股票期權及限制性股票激勵計劃(以下簡稱“激勵計劃”)中首次授予部分的股票期權的行權價格調整為3.93元/股、預留部分授予的股票期權的行權價格調整為3.52元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.